Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 166 clinical trials
Efficacy of HAD Induction With Intensified Cytarabine in Newly-diagnosed CEBPA Double Mutated Acute Myeloid Leukemia

(homoharringtonine(HHT)+cytarabine+daunorubicin) with intermediate dose cytarabine improved the survival of AML, especially in patients with CEBPA double mutation.

daunorubicin
cytarabine
ejection fraction
acute promyelocytic leukemia
acute leukemia
  • 0 views
  • 15 Aug, 2021
  • 1 location
SKLB1028, Daunorubicin, and Cytarabine in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)

The purpose of this study is to describe the dose limiting toxicities (DLT) of SKLB1028 when combined with cytarabine/ daunorubicin remission induction in a 7+3 schedule. Safety and tolerability

  • 0 views
  • 22 Jul, 2022
  • 1 location
Clofarabine Idarubicin Cytarabine Vincristine Sulfate and Dexamethasone in Treating Patients With Newly Diagnosed or Relapsed Mixed Phenotype Acute Leukemia

This phase II trial studies how well clofarabine, idarubicin, cytarabine, vincristine sulfate, and dexamethasone work in treating patients with mixed phenotype acute leukemia that is newly

idarubicin
cytarabine
dexamethasone
clofarabine
acute leukemia
  • 22 views
  • 05 Nov, 2021
  • 1 location
Decitabine+Cladribine+Cytarabine+Granulocyte Colony-stimulating Factor (D-CLAG) for Relapsed or Refractory Acute Myeloid Leukemia (AML)

A prospective, single-arm, multicenter, exploratory study to evaluate the efficacy and safety of D-CLAG regimen in the treatment of relapsed or refractory acute myeloid leukemia

idarubicin
cytarabine
acute leukemia
granulocyte colony stimulating factor
decitabine
  • 1 views
  • 05 Mar, 2022
  • 1 location
A Prospective Study for the Treatment of Children With Newly Diagnosed LCH Using a Cytarabine Contained Protocol

hematological malignancies. This finding deserves to be tested in prospective clinical trials with long-term follow-up. Cytarabine has been applied for patients with LCH but has never been evaluated in our

  • 0 views
  • 06 Mar, 2021
  • 1 location
Uproleselan Cladribine and Low Dose Cytarabine for the Treatment of Patients With Treated Secondary Acute Myeloid Leukemia

This phase Ib/II trial finds out the best dose and effect of cladribine and low dose cytarabine when given in combination with uproleselan in treating patients with treated secondary acute

  • 0 views
  • 05 Jul, 2021
  • 1 location
Liposomal Cytarabine Daunorubicin and Gemtuzumab Ozogamicin for the Treatment of Relapsed Refractory Pediatric Patients With Acute Myeloid Leukemia

This phase I trial studies the best dose and side effects of liposomal cytarabine, daunorubicin, and gemtuzumab ozogamicin in treating pediatric patients with acute myeloid leukemia that has

  • 0 views
  • 13 Jun, 2021
  • 1 location
Accelerated Dose Schedule of Cytarabine Consolidation Therapy for Older Patients With Acute Myeloid Leukemia (AML) in Complete Remission

This phase 2, open label, non-randomized study will evaluate the safety of administering high dose cytarabine (HiDAC) consolidation therapy on days 1-3 of each cycle, as compared to standard

cytarabine
induction chemotherapy
consolidation therapy
remission
blast cells
  • 0 views
  • 02 Jan, 2022
  • 1 location
Lintuzumab-Ac225 in Combination With Cladribine + Cytarabine + Filgastrim + Mitoxantrone (CLAG-M) for Relapsed/Refractory Acute Myeloid Leukemia

This is a prospective, single-center phase I clinical study aimed at determining the maximum-tolerated dose, recommended phase 2 dose and safety of Lintuzumab-Ac225 in combination with CLAG-M chemotherapy in the management of relapsed/refractory acute myeloid leukemia. This study uses a 3+3 design with a five-patient cohort at the recommended phase …

cytarabine
mitoxantrone
flow cytometry
myeloproliferative disorder
granulocyte colony stimulating factor
  • 14 views
  • 05 May, 2022
  • 1 location
Liposomal Cytarabine and Daunorubicin (CPX-351) and Quizartinib for the Treatment of Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome

-351, composed of chemotherapy drugs daunorubicin and cytarabine, works in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping

cytarabine
cytarabine/daunorubicin
hemolysis
hematopoietic growth factors
ejection fraction
  • 5 views
  • 11 Jul, 2022